Anebulo Pharmaceuticals, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
2Anebulo Pharmaceuticals's Business Model
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
About Anebulo Pharmaceuticals
Website: https://www.anebulo.com
CEO (Chief Executive Officer): Mr. Richard Anthony Cunningham
IPO date: 2021-05-07
Contact
Country: US
Address: 1415 Ranch Road 620 South
City: Lakeway
State: TX
Phone: 512 598 0931
Zip Code: 78734
Other
CIK: 0001815974
ISIN: US0345691036
CUSIP: 034569103
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
